window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

weight management

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial

    CORXEL Pharmaceuticals reported positive Phase 2 results for oral GLP-1 [...]

    June 24, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Currax highlights peer-reviewed review supporting combination approaches in obesity treatment

    Currax Pharmaceuticals is highlighting a peer-reviewed publication supporting the use [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Patient voices take centre stage as Currax leans into authenticity in obesity care

    As debate continues over the cost and sustainability of GLP-1 [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA grants Fast Track status to SOTIO’s colorectal cancer ADC ahead of Phase 1/2 trial
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • EpilepsyGTx partners with ClearPoint Neuro to support Phase 1 gene therapy trial
    Categories: Advanced Therapies, Clinical & Regulatory, Drug Delivery & Formulation, Research & Development
  • Skyhawk expands global Huntington’s disease trial following positive Phase 1/2 data
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top